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ABSTRACT
The prognostic value of pre-treatment Epstein-Barr Virus (EBV) DNA viral load for 
non-endemic, locally-advanced, EBV-related nasopharyngeal cancer (NPC) patients is 
yet to be defined. All patients with EBV encoded RNA (EBER)-positive NPC treated at 
our Institution from 2005 to 2014 with chemotherapy (CT) concurrent with radiation 
(RT) +/- induction chemotherapy (ICT) were retrospectively reviewed. Pre-treatment 
baseline plasma EBV DNA (b-EBV DNA) viral load was detected and quantified by PCR. 
Median b-EBV DNA value was correlated to potential influencing factors by univariate 
analysis. Significant variables were then extrapolated and included in a multivariate linear 
regression model. The same variables, including b-EBV DNA, were correlated with Disease 
Free Survival (DFS) and Overall Survival (OS) by univariate and multivariate analysis.
A total of 130 locally-advanced EBER positive NPC patients were evaluated. 
Overall, b-EBV DNA was detected in 103 patients (79.2%). Median viral load was 
554 copies/mL (range 50–151075), and was positively correlated with T stage 
(p=0.002), N3a-b vs N0-1-2 stage (p=0.048), type of treatment (ICT followed by 
CTRT, p=0.006) and locoregional and/or distant disease recurrence (p=0.034). In the 
overall population, DFS and OS were significantly longer in patients with pre-treatment  
negative EBV DNA than in positive subjects at the multivariate analysis.
Negative b-EBV DNA can be considered as prognostic biomarker of longer 
DFS and OS in NPC in non-endemic areas. This finding needs confirmation in larger 
prospective series, with standardized and inter-laboratory harmonized method of 
plasma EBV DNA quantification.
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INTRODUCTION
Nasopharyngeal cancer (NPC), commonly affecting 
Asian countries (incidence rate as high as 20-50 per 
100.000 persons/year), is a very rare disease in Caucasian 
countries (0.5 new cases/year per 100.000 persons/year) 
[1, 2]. Epstein-Barr Virus (EBV) is one of the most 
important causative factors of NPC. It has a heterogeneous 
diffusion, which might account, at least in part, for the 
different incidence between Southern China or Southeast 
Asia (endemic area) and Europe or USA (non-endemic 
area).
In the endemic area, the prognostic role of plasma 
EBV DNA viral load, with different cut-offs and detected 
before curative treatment for locally-advanced NPC 
patients, has been well described [3, 4, 5, 6].
To our knowledge, in the non-endemic area, only 
two limited case series (34 and 36 patients, respectively) 
investigating the role of EBV DNA have been reported 
[7, 8]. These studies showed a direct relationship between 
pre-treatment EBV DNA viral load and baseline clinical 
tumor stage, and between EBV DNA increase and tumor 
recurrence during follow-up. Ferrari et al. [8] tried to 
demonstrate a prognostic significance of pre-treatment 
EBV DNA by reporting a significant correlation between 
higher baseline EBV DNA values and shorter Disease-
Free Survival (DFS) at univariate analysis (not confirmed 
after adjusting for age).
Therefore, the role of pre-treatment EBV DNA 
quantification for NPC patients in a non-endemic areas 
remains undefined. This study evaluates the prognostic 
role of baseline EBV DNA viral load for locally-advanced 
EBV-related NPC patients in a non-endemic area.
RESULTS
Study population
As shown in Table 1, 130 EBER-positive NPC 
patients were treated at our Institution with curative 
intent. The majority of patients were males (66.9%), 
in good clinical conditions (ECOG PS 0-1: 95.4%), 
young (median age: 48.5, range: 18-81 years), mainly 
staged as locally-advanced disease (86.2%: III-IV 
stage) and treated with induction chemotherapy before 
concomitant CTRT (77.7%: ICT with CTRT). One out 
of 5 patients was referred to our hospital after diagnostic 
neck surgery. The median b-EBV DNA viral load was 
554 copies/mL with only 5 (3.8%) positive UQ and 27 
(20.8%) negative patients. At a median follow-up of 43 
months (range: 11-122) 28 patients recurred (21.5%) 
and 18 (13.9%) had died. The majority of recurrences 
(24/28; mean month: 37.9, median month: 38, range: 
7-60 months) and all deaths (mean month: 40.9, median 
month: 43, range: 11-60 months) occurred within 5 years 
of follow-up.
b-EBV DNA and its influencing factors
Median b-EBV DNA viral load was significantly 
higher (Table 2) in patients with: ICT followed by CTRT 
(P=0.006), higher tumor T and N stage (T4 and N3a-3b, 
P=0.002 and P=0.048), locoregional and/or distant disease 
recurrence (P=0.034).
b-EBV DNA and outcome variables (DFS, OS)
At univariate analysis, DFS was significantly longer 
in females (P=0.035), patients who underwent neck 
surgery (P=0.035), and those with lower T-stage (T1-2-3, 
P=0.006) and negative b-EBV DNA values (P=0.002). OS 
was significantly longer in low T-staged (T1-2-3, P=0.018) 
and negative b-EBV DNA NPC patients (P=0.027). At 
multivariate analysis, only b-EBV DNA negativity (vs 
positivity) was confirmed as significantly independent 
influencing factor for both DFS and OS (P=0.05 and 
P=0.06, respectively). Kaplan-Meier survival curves 
(Figures 1, 2) showed a significant relationship between 
b-EBV DNA status (negative vs positive) and outcome 
variables (DFS, P=0.032 and OS, P=0.029).
Identification of b-EBV DNA cut-off influencing 
outcome
Considering b-EBV DNA as a categorical variable 
stratified into the 4 groups (Table 3), we disclosed a 
significant relationship between b-EBV DNA and DFS/
OS. The UQ, Q and Q+ b-EBV DNA groups showed 
similar results, thus suggesting that UQ behave as Q and 
Q+. In order to verify this hypothesis, we re-run the test 
after grouping together UQ and Q. The results were the 
same (Table 3) and the relationship between b-EBV DNA 
and DFS and OS remained significant (P<0.001), like 
when UQ and Q were considered separately. Using these 
three groups (UQ and Q, Q+, and Neg), we found that 
the UQ and Q group had the same behaviour as the Q+ 
group, whereas both differed from the Neg (Figure 3), thus 
suggesting that b-EBV DNA can be considered as a binary 
variable (positive or negative) regardless of the number of 
copies measured.
By ROC curve analysis (Area Under the Curve, 
AUC=0.640, P=0.009) a b-EBV DNA value of 3493 
copies/mL (Figure 4) was identified as cut-off of higher 
risk for loco-regional and/or distant recurrence with an 
accuracy of 72% (sensitivity: 53%; specificity: 76%).
b-EBV DNA and outcome variables (DFS, OS) in 
a filtered-treatment study population
The median b-EBV DNA value was 885 copies/
mL (range: 0 – 151075) in a filtered-treatment study 
population including only patients treated with ICT 
followed by CTRT (N=101). According to the results 
obtained in the overall population, b-EBV DNA was 
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considered as a binary variable (positive/negative) and 
was significantly related with DFS (P=0.004) and OS 
(P=0.019) at univariate analysis.
Figures related to Kaplan-Meier survival curves 
(Supplementary Figure 1, Supplementary Figure 2) and 
the Tukey HSD post-hoc analysis results (Supplementary 
Figure 3) of the filtered-treatment study population are 
available as supplementary materials.
DISCUSSION
We showed the prognostic value of pre-treatment 
plasma EBV DNA viral load in a relatively high number 
of non-endemic EBV-related NPC patients. To date, all 
data regarding this issue derived from the main clinical 
trials conducted in the endemic area [3, 4, 6].
Table 1: Baseline characteristics of study population and descriptive statistics
Characteristics N (% or range)
Gender  
 M 87 (66.9)
 F 43 (33.1)
Median Age 48.5 (18-81)
ECOG Performance Status  
 0-1 124 (95.4)
 2 6 (4.6)
Treatment  
 ICT followed by CTRT 101 (77.7)
 CTRT 29 (22.3)
Neck surgerya  
 YES 26 (20)
 NO 104 (80)
Stage (VII AJCC)  
 II 18 (13.8)
 III 40 (30.8)
 IVa 26 (20)
 IVb 46 (35.4)
Median EBV DNA 554 (0-151075)
EBV DNAb  
 UQ 5 (3.8)
 Neg 27 (20.8)
 Q 50 (38.5)
 Q+ 48 (36.9)
Relapse 28 (21.5)
 Locoregional 12 (42.9)
 Distant 16 (57.1)
Death 18 (13.9)
 Due to disease 15 (83.3)
 Due to other causes 3 (16.7)
ECOG: Eastern Cooperative Oncology Group.
AJCC: American Joint Committee on Cancer.
a Lymph node neck dissection or excisional biopsy.
b EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable (0 < EBV 
DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 x 102 copies/mL); Q+, Strongly positive and 
quantifiable (EBV DNA > 15 x 102 copies/mL).
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The median copy number of b-EBV DNA (554 
copies/mL) and the prevalence of positivity (79.2%) of 
plasma EBV DNA were quite lower than in the endemic 
area (median copy number: 681 for stage III, 1703 for 
stage IV; percentage of positivity: 94.9%) [3].
The median b-EBV DNA value resulted significantly 
higher in patients with more advanced disease stage and/
or treated with ICT. The former observation reflects the 
correlation with the disease burden [9, 10, 11, 12, 13]; 
the latter may be explained by the fact that, during the 
entire time of our analysis, one of the criteria we adopted 
as Institutional policy for choosing ICT was b-EBV DNA 
higher than 15×102 copies/mL as well as T4 and/or N3 
disease.
At multivariate analysis, b-EBV DNA value 
correlated with both recurrence of disease and survival 
outcomes (DFS, OS), overcoming the variable of ICT.
Differing from what observed in endemic NPC 
populations [3, 4, 5, 6], we were not able to identify 
any cut-off of b-EBV DNA as influencing DFS and OS. 
The few (N=5) patients with unquantifiable positivity of 
b-EBV DNA, showed a similar behaviour as all other 
detectable b-EBV DNA groups thus supporting the 
informative baseline power of the test.
Our ROC curve analysis identified in 3493 copies/
mL a cut-off associated with an increased risk of loco-
regional and/or distant disease recurrence confirming in 
non-endemic area a trend of correlation between b-EBV 





Gender   
 M 545 0.094
 F 577  
ECOG Performance Status   
 0-1 549.5 0.112
 2 6820  
Treatment   
 ICT followed by CTRT 885 0.006
 CTRT 179  
Neck surgeryc   
 YES 835 0.083
 NO 226.5  
T classification   
 1-2-3 387 0.002
 4 1745  
N classification   
 0-1-2 453 0.048
 3a-3b 2153  
Recurrence   
 YES 4609 0.034
 NO 480  
a Excluded from this analysis the Unquantifiable EBV DNA group (N=5).
b Continuous variable (age) was assessed using Spearman’s correlation; categorical variables were assessed using non-
parametric Mann-Whitney test.. Statistically significant P values (P<0.05) are highlighted.
c Lymph node neck dissection or excisional biopsy.
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Figure 1: Kaplan-Meier survival curves showing the probability of DFS in locally advanced EBER positive NPC 
patients. DFS= Disease Free Survival. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but 
UnQuantifiable (0 < EBV DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 x 102 copies/mL); Q+, Strongly 
positive and quantifiable (EBV DNA > 15 x 102 copies/mL).
Figure 2: Kaplan-Meier survival curves showing the probability of OS in locally advanced EBER positive NPC patients. 
OS= Overall Survival. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable (0 < EBV 
DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 x 102 copies/mL); Q+, Strongly positive and quantifiable (EBV 
DNA > 15 x 102 copies/mL).
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 UQ 13 13
 Neg 62 62
 Q 27 31
 Q+ 33.5 37.5
3 Groups     
 UQ, Q 23
0.0001 
26
0.0002  Q+ 33.5 37.5
 Neg 62 62
a EBV DNA was stratified into 4 and 3 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable (0 < EBV 
DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 x 102 copies/mL); Q+, Strongly positive and 
quantifiable (EBV DNA > 15 x 102 copies/mL).
b The categorical variables were assessed using non-parametric Kruskal Wallis ANOVA. Statistically significant P values 
(P<0.05) are highlighted.
Figure 3: Results of Tukey HSD test. EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but 
UnQuantifiable (0 < EBV DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 x 102 copies/mL); Q+, Strongly positive 
and quantifiable (EBV DNA > 15 x 102 copies/mL). The upper panel shows the results of the Tukey’s HSD test: P values corresponding 
to the difference between group pairs are displayed. Highlighted values are statistically significant (P<0.05). The lower panel shows the 
median values of the three groups and their confidence intervals.
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DNA values progressively rising over the upper normal 
limits and recurrence.
This is in line with the results shown in an endemic 
population by Leung on 2003 [5] and Chen on 2016 [6]. 
They both found a cut-off of 4000 copies/mL for higher 
risk of development of distant metastases, which is one of 
the most important causes of treatment failure.
The main limitation of our analysis is the use of 
a laboratory method to measure circulating EBV DNA 
different from that used in the most robust published 
studies establishing the prognostic value of EBV DNA 
in NPC [3, 4], in which the primer/probe sets as target 
the BamHI-W region of the EBV genome [14]. BamHI-W 
fragment is repeated 8 to 11 times in the EBV genome, 
thus allowing more sensitive detection when compared 
with a single copy EBV genes [15, 16], such as Latent 
Membrane Protein (LMP2), Polymerase1 (POL1) or 
Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1). This 
latter was used in this study and may explain why we 
identified a category (the UQ group) that has never been 
reported before. Possibly, a higher-sensible methodology 
could have moved this UQ category to the quantifiable 
group. Moreover, these discrepancies of the laboratory 
evaluations may be the reasons why we did not find 
a specific cut-off to significantly impact on outcome. 
Furthermore, the use of this different laboratory method 
could also explain why we detected a lower prevalence 
of positivity and median copy number of EBV DNA 
compared with endemic populations; to this respect, 
however, we cannot rule out that genetic factors (i.e., 
different genetic profile between Asian and non-Asian 
populations) have played a role.
On the other hand, the EBV DNA detection method 
targeting BamHI-W, which is a very variously repeated 
region among all EBV strains genomes, could be linked to 
a higher inter-subjects variability rate.
The commutability of all EBV DNA values across 
all different methods is a very debated issue [17, 18]. 
Le QT et al. [19] already stated that a prompt assay 
standardization is mandatory to reduce the intra and inter-
laboratory variability to ensure a better comparison of all 
worldwide collected plasma EBV DNA samples.
Another limitation of our analysis is the non-
homogeneous characteristic of the retrieved data. The 
main imbalance was due the high rate of patients having 
performed an ICT before locoregional treatment. However, 
we also demonstrated that this variable did not influence 
the prognostic value of b-EBV DNA.
Another weakness of our study is the lack of 
information about the post-treatment EBV DNA viral load 
detection which has already been recognized in endemic 
area as significantly related to worse prognosis when still 
detectable for 1 week [3, 4, 20] to 1 month-time after 
chemo-radiotherapy completion [21]. Noteworthy, two 
ongoing randomized, phase III trials (NCT00370890 and 
NCT02363400) will evaluate NPC patients with residual 
EBV DNA to adjuvant chemotherapy or clinical observation 
only. The results of those trials will help to understand if 
post-treatment EBV DNA is the best factor for identifying 
patients more likely to benefit of the adjunctive therapies.
Figure 4: Results of ROC curve analysis for the individuation of a possible value of b-EBV DNA as cut-off of higher 
risk of locoregional/distant recurrence. Top panel: ROC curve. The x-axis is (1-Specificity); the y-axis is Sensitivity, Area Under 
the Curve (AUC) = 0.64, P=0.009. Bottom panel: values of Specificity, Sensitivity, Accuracy, and Specificity+Sensitivity corresponding 
to the cut-off value of 3493 copies/mL. The lower and upper confidence intervals for Specificity and Sensitivity are reported in brackets.
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However, based on our findings that suggest a 
prognostic value of pre-treatment EBV DNA in patients 
belonging to non-endemic areas, we advocate for 
international cooperation to allow for standardized and 
inter-laboratory harmonized method of plasma EBV 
detection. A routinary and comparable quantification of 
EBV DNA may be of relevance for a timely monitoring of 
disease even in other settings, such as the follow-up phase 
and metastatic stage.
MATERIALS AND METHODS
We evaluated the pre-treatment baseline plasma 
EBV DNA (b-EBV) analysed in all EBV positive NPC 
patients treated with curative intent at the National Cancer 
Institute of Milan – a referral Center for the treatment of 
oncological disease in Northern Italy - from March 2005 
to May 2014. EBV infection was determined by EBV 
encoded RNAs (EBER) in situ hybridization.
EBV DNA detection
EBV DNA levels were measured on plasma 
samples by real-time quantitative polymerase chain 
reaction (q-PCR) and were expressed as copies/mL. 
This measurement was performed at two Hospitals of 
Milan, Niguarda Ca’ Granda Hospital and San Raffaele 
Hospital. Viral DNA extraction was performed by using 
the NucliSENS easyMAG kit (BioMérieux, Lyon, France) 
in Niguarda Hospital and Qiagen MDX kit in San Raffaele 
Hospital. In both Hospitals, EBV DNA quantification 
was performed by EBV Elite MGB kit according to the 
manifacturer’s instructions. The system amplified the gene 
coding for Epstein-Barr Virus Nuclear Antigen 1 (EBNA-
1) protein.
The linear range of the assay was 102-107 copies/mL 
and the results of EBV DNA were expressed as follows: 
Not detected; Detected and Quantifiable (≥102 copies/mL); 
Detected but UnQuantifiable [UQ] (< 102 copies/mL).
Oncologic treatment
Patients were treated with chemo-radiotherapy 
(CTRT) with or without induction chemotherapy (ICT) 
according to the standard practice of our Institute.
Radiotherapy
All patients were treated with intensity modulated 
radiotherapy (RT) techniques (IMRT, Intensity Modulated 
Radiation Therapy or VMAT, Volumetric Modulated Arc 
Therapy), with a curative intent. In all patients, total 
prescription dose was 70 Gy, either by conventional 
fractionation (2 Gy per fraction, 5 fractions per week) 
or a moderately-hypofractionated regimen (2.12 Gy per 
fraction, 5 fractions per week), using a sequential or 
simultaneous integrated boost approach. All patients were 
staged with MRI of the head and neck district and whole 
body PET-CT scan before the initiation of oncological 
therapy; all images were fused with planning CT scans to 
better define target volumes. In patients receiving ICT, the 
extent of disease was re-evaluated with MRI after the last 
chemotherapy cycle. Planning procedures were usually 
performed shortly after the completion of ICT, and RT 
usually started within 3 to 4 weeks from the last cycle of 
induction chemotherapy.
Chemotherapy
In line with Institutional policies, ICT was 
prescribed in patients with: a) clinically-staged T4 
and/or N3a-b NPC; b) Neck surgery (lymph node 
neck dissection or excisional biopsy) performed for 
diagnostic purposes; c) b-EBV DNA higher than 15x102 
copies/mL according to the strongest dismal prognostic 
cut-off of b-EBV DNA recognized by Lin et al. [3]. 
In more details, Lin et al. showed that endemic NPC 
patients with baseline plasma EBV DNA concentrations 
< 1500 copies/mL had better outcomes (in terms of OS 
and DFS) compared with those with pre-treatment EBV 
DNA values ≥1500 copies/mL.
ICT was administered with TPF schedule for 3 
cycles every 3 weeks (docetaxel 75 mg/sm on day 1, 
cisplatin 75 mg/sm on day 1, 5-fluororuracil 750 mg/sm/
day on days 1 to 4) followed by antibiotic prophylaxis 
(ciprofloxacin at 500 mg dose twice a day as standard) 
from 5th to 15th day after chemotherapy initiation. The use 
of growth-stem cell factors (G-CSF) as primary prevention 
for chemo-related neutropenia was limited to patients 
with intracranial disease or at high-risk of infection 
development. Concomitant chemotherapy regimen was 
weekly (50 mg/sm) or 3-weekly (100 mg/sm) cisplatin 
(carboplatin AUC 5 was preferred if baseline creatinine 
clearance was lower than 60 ml/min).
Statistical analysis
Descriptive statistics were calculated over main 
baseline patients [gender, age, Eastern Cooperative 
Oncology Group Performance Status (ECOG PS)], disease 
(T stage, N stage, VII AJCC Stage, locoregional and/or 
distant recurrence) and treatment characteristics (CTRT, 
CTRT with ICT, Neck Surgery).
We first investigated the relationship of b-EBV 
DNA viral load with all patients, disease, and treatment-
related characteristics that could be considered influencing 
factors.
Univariate analysis was performed: non-parametric 
Mann-Whitney test (Gender, ECOG PS, CTRT vs 
CTRT with ICT, Neck Surgery) or non-parametric 
Kruskal Wallis ANOVA (T stage, N stage) was used for 
categorical variables (P<0.05). Spearman’s correlation 
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(Age) was used for continuous variables (P<0.05). 
Subjects with positive UQ EBV DNA value were 
excluded from this analysis; patients with T stage 1, 2, 
and 3 were grouped together and compared with patients 
with T stage 4, while patients with N stage 0, 1, and 2 
were grouped together and compared with patients with 
N stage 3a and 3b.
Second, we investigated the relationship of outcome 
variables (DFS, OS) with the above-mentioned influencing 
factors and with b-EBV DNA. To this end, EBV DNA was 
stratified into 4 groups:
1. Negative (Neg): b-EBV DNA = 0 copies/mL;
2. Positive but UnQuantifiable (UQ): 0 < b-EBV 
DNA <102 copies/mL;
3. Positive and quantifiable (Q): 102 ≤ b-EBV DNA 
≤15×102 copies/mL;
4. Strongly positive and quantifiable (Q+): b-EBV 
DNA >15×102 copies/mL.
A cut-off of 15×102 copies/mL was chosen in 
accordance with existing evidence [3], as previously 
mentioned. Tukey’s Honest test was used for post-hoc 
analysis (P<0.05).
Survival analysis (Kaplan-Meier) was conducted on 
OS and DFS with respect to all the variables that resulted 
significant at the univariate analysis.
In order to verify our results in a homogenously 
treated cohort of patients, we considered separately the 
subgroup of patients treated with ICT followed by CTRT 
or with CTRT alone. The same analysis described for the 
entire population was conducted in this subgroup. Last, 
a ROC analysis was performed on EBV DNA values in 
order to establish the threshold value that might better 
discriminate patients with recurrence from patients 
without recurrence.
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